Showing 1236 results
-
Media Release /Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder,…
-
Media Release /The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan…
-
Media Release /Die Vereinbarung für die kommenden fünf Jahre umfasst Spenden von Behandlungseinheiten im Wert von mehr als USD 40 Millionen, mit denen rund 1,3 Millionen Patienten geholfen werden…
-
Media Release /Ce nouvel engagement sur cinq ans comprend un don de médicaments d'une valeur estimée à plus d'USD 40 millions qui devrait permettre de traiter environ 1,3 million de patients Le nouveau…
-
Media Release /Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers…
-
Media Release /New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact…
-
Media Release /Das International Biotechnology Leadership Camp (BioCamp) fördert das Interesse von Studierenden für wissenschaftlichen Fortschritt und unternehmerische Chancen Anlässlich des interaktiven Programms…
-
Media Release /L'International Biotechnology Leadership Camp (BioCamp) mobilise des étudiants autour d'avancées scientifiques et d'opportunités entrepreneuriales. Ce programme interactif a réuni au siège de…
-
Media Release /The International Biotechnology Leadership Camp (BioCamp) engages students around scientific advances and entrepreneurial opportunities The interactive program brought 70 university students…
-
Media Release /New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12…